These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20613786)

  • 1. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
    Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
    Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome].
    Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
    Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF
    Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
    Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
    Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system.
    Morita Y; Matsuda M; Hanamoto H; Shimada T; Tatsumi Y; Maeda Y; Kanamaru A
    Clin Immunol; 2004 Oct; 113(1):109-16. PubMed ID: 15380536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
    De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
    Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes.
    Zhao ZG; Xu W; Yu HP; Fang BL; Wu SH; Li F; Li WM; Li QB; Chen ZC; Zou P
    Cancer Lett; 2012 Apr; 317(2):136-43. PubMed ID: 22240014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
    Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
    Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
    Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.
    Kiladjian JJ; Bourgeois E; Lobe I; Braun T; Visentin G; Bourhis JH; Fenaux P; Chouaib S; Caignard A
    Leukemia; 2006 Mar; 20(3):463-70. PubMed ID: 16408099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [STAT5 phosphorylation in CD34(+)CD38(-)CD123(+) bone marrow cells of the patients with myelodysplastic syndrome].
    Liu BN; Fu R; Wang HQ; Li LJ; Yue LZ; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Xing LM; Guan J; Wang J; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):480-3. PubMed ID: 22967386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome.
    Micheva I; Thanopoulou E; Michalopoulou S; Kakagianni T; Kouraklis-Symeonidis A; Symeonidis A; Zoumbos N
    Br J Haematol; 2004 Sep; 126(6):806-14. PubMed ID: 15352984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.